Pharmaceutical - fostamatinib

Filter

Current filters:

fostamatinib

Popular Filters

Rigel shares fall as asthma compound fails to meet primary endpoint

27-08-2013

Shares of USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) fell 10% to $3.27 in morning trading yesterday…

AstraZenecafostamatinibNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRigel Pharmaceuticals

AstraZeneca returns fostamatinib program rights to Rigel

04-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Rigel Pharmaceuticals (Nasdaq: RIGL) today…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibLicensingPharmaceuticalResearchRigel Pharmaceuticals

Mixed top-line results for AstraZeneca's RA drug candidate fostamatinib

05-04-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning reported top-line results from the Phase…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibPharmaceuticalResearch

AstraZeneca presents mixed data on fostamatinib in RA

13-12-2012

Shares of Anglo-Swedish drug major AstraZeneca (LSE: AZN) fell 2.1% to $47.88 in premarket US trading…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibPharmaceuticalResearchRigel Pharmaceuticals

AstraZeneca gains rights to Rigel's asthma candidate R256

20-06-2012

Anglo Swedish drug major AstraZeneca (LSE: AZN) and signed an exclusive global license accord with USA-based…

AstraZenecafostamatinibLicensingPharmaceuticalR256Respiratory and PulmonaryRigel Pharmaceuticals

Unexpectedly strong data for Galapagos rheumatoid arthritis drug candidate

24-11-2011

Shares of Belgium-based biotech firm Galapagos (Euronext: GLPG) jumped 22% on Tuesday and a further 12%…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibGalapagosPfizerPharmaceuticalResearchtofacitinib

Back to top